{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:16:23Z","timestamp":1782227783237,"version":"3.54.5"},"reference-count":58,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment policy of chronic myeloid leukemia (CML), particularly with tyrosine kinase inhibitors, has been influenced by several recent studies that were well designed and rapidly performed, but their interpretation is of some concern because different end points and methodologies were used. To understand and compare the results of the previous and future studies and to translate their conclusion into clinical practice, there is a need for common definitions and methods for analyses of CML studies. A panel of experts was appointed by the European LeukemiaNet with the aim of developing a set of definitions and recommendations to be used in design, analyses, and reporting of phase 3 clinical trials in this disease. This paper summarizes the consensus of the panel on events and major end points of interest in CML. It also focuses on specific issues concerning the intention-to-treat principle and longitudinal data analyses in the context of long-term follow-up. The panel proposes that future clinical trials follow these recommendations.<\/jats:p>","DOI":"10.1182\/blood-2011-10-383711","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T05:35:36Z","timestamp":1334640936000},"page":"5963-5971","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":75,"title":["Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet"],"prefix":"10.1182","volume":"119","author":[{"given":"Jo\u00eblle","family":"Guilhot","sequence":"first","affiliation":[{"name":"Inserm CIC 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. and A. Ser\u00e0gnoli,\u201d S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Hematology, Royal Liverpool University Hospital, University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Clinic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[{"name":"Inserm CIC 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Abteilung H\u00e4matologie\/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Kulikov","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hemato and Oncology, University Hospital Brno, Central European Institute of Technology, Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Petzer","sequence":"additional","affiliation":[{"name":"Internal Medicine I, Hematology and Medical Oncology, Barmherzige Schwestern Hospital Linz, Linz, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology \u201cL. and A. Ser\u00e0gnoli,\u201d S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Versailles Saint-Quentin-en-Yvelines, Le Chesnay, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, University at Orbasano, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[{"name":"III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Uppsala and"},{"name":"Department of Hematology, University Hospital, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Luis","family":"Steegmann","sequence":"additional","affiliation":[{"name":"Hematolog\u00eda, Hospital Universitario de la Princesa, Madrid, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Zaritskey","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Almazov Federal Centre of Heart, Blood and Endocrinology, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim, Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111808194456300_B1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"9584","key":"2019111808194456300_B2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia.","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"2019111808194456300_B3","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"issue":"21","key":"2019111808194456300_B4","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials:","volume":"89","author":"Chronic Myeloid Leukemia Trialists' Collaborative Group","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111808194456300_B5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1365-2141.2000.02229.x","article-title":"Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials.","volume":"110","author":"Chronic Myeloid Leukemia Trialists' Collaborative Group","year":"2000","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111808194456300_B6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111808194456300_B7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111808194456300_B8","first-page":"335","article-title":"The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.","volume":"90","author":"Hasford","year":"2005","journal-title":"Haematologica"},{"issue":"32","key":"2019111808194456300_B9","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808194456300_B10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"2019111808194456300_B11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111808194456300_B12","volume-title":"Analysis of Survival Data","author":"Cox","year":"1984"},{"key":"2019111808194456300_B13","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4612-4348-9","volume-title":"Statistical Models Based on Counting Process","author":"Andersen","year":"1993"},{"issue":"11","key":"2019111808194456300_B14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808194456300_B15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate endpoints in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"issue":"12","key":"2019111808194456300_B16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808194456300_B17","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated interferon-\u03b12b with imatinib increases molecular response rates in patients with low or intermediate risk chronic myeloid leukemia.","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"26","key":"2019111808194456300_B18","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus pegylated interferon-alpha2a in chronic myeloid leukemia.","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111808194456300_B19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/cncr.26391","article-title":"Suboptimal responses in chronic myeloid leukemia: implications and management strategies.","volume":"118","author":"Jabbour","year":"2012","journal-title":"Cancer"},{"issue":"35","key":"2019111808194456300_B20","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808194456300_B21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European LeukemiaNet Management recommendations.","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"issue":"24","key":"2019111808194456300_B22","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111808194456300_B23","article-title":"Evolution of definitions of response, progression-free survival, and event-free survival in front-line studies of chronic myeloid leukemia [published online ahead of print, February 13, 2012].","author":"Ansstas","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111808194456300_B24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111808194456300_B25","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute\n          Common Terminology Criteria for Adverse Events (CTCAE), Version v403.\n          Accessed June 14, 2010\n          \n            http:\/\/eversusnci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06\/14QuickReference_5x7.pdf"},{"issue":"7","key":"2019111808194456300_B26","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory.","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"4","key":"2019111808194456300_B27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications.","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"issue":"23","key":"2019111808194456300_B28","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","article-title":"Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111808194456300_B29","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111808194456300_B30","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111808194456300_B31","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111808194456300_B32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808194456300_B33","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111808194456300_B34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V118.21.785.785","article-title":"The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first-line therapy.","volume":"118","author":"Marin","year":"2011","journal-title":"Blood"},{"key":"2019111808194456300_B35","unstructured":"FDA: Clinical trial endpoints for the approval of cancer drugs and biologics: U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Clinical\/Medical.\n          Accessed May 2007\n          \n            http:\/\/www.fda.gov\/downloads\/drugsGuidanceComplianceRegulatoyInformation\/Guidance\/UCM071590.pdf"},{"issue":"17","key":"2019111808194456300_B36","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products.","volume":"27","author":"Fleming","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808194456300_B37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/sim.3762","article-title":"Estimating the crude probability of death due to cancer and other causes using relative survival models.","volume":"29","author":"Lambert","year":"2010","journal-title":"Stat Med"},{"issue":"3","key":"2019111808194456300_B38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.21942","article-title":"Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?","volume":"86","author":"Zackova","year":"2011","journal-title":"Am J Hematol"},{"issue":"17","key":"2019111808194456300_B39","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111808194456300_B40","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/blood.V118.21.3132.3132","article-title":"International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML).","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"2019111808194456300_B41","volume-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"issue":"4","key":"2019111808194456300_B42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"6","key":"2019111808194456300_B43","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","article-title":"Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.","volume":"66","author":"Sokal","year":"1985","journal-title":"Blood"},{"issue":"6","key":"2019111808194456300_B44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111808194456300_B45","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/MLR.0b013e3181d99107","article-title":"Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.","volume":"48","author":"Varadhan","year":"2010","journal-title":"Med Care"},{"issue":"9","key":"2019111808194456300_B46","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2019111808194456300_B47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2531637","article-title":"Protecting against non-randomly missing data in longitudinal studies.","volume":"46","author":"Brown","year":"1990","journal-title":"Biometrics"},{"key":"2019111808194456300_B48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2307\/2986113","article-title":"Informative drop-out in longitudinal data analysis.","volume":"43","author":"Diggle","year":"1994","journal-title":"Appl Stat"},{"issue":"7","key":"2019111808194456300_B49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.annepidem.2009.03.018","article-title":"Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement.","volume":"19","author":"Ziogas","year":"2009","journal-title":"Ann Epidemiol"},{"issue":"6","key":"2019111808194456300_B50","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/sim.4780100609","article-title":"Multiple testing in clinical trials.","volume":"10","author":"Bauer","year":"1991","journal-title":"Stat Med"},{"issue":"3","key":"2019111808194456300_B51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/biomet\/63.3.655","article-title":"On closed testing procedures with special reference to ordered analysis of variance.","volume":"63","author":"Marcus","year":"1976","journal-title":"Biometrika"},{"issue":"3","key":"2019111808194456300_B52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials.","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"issue":"12","key":"2019111808194456300_B53","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.3324\/haematol.2009.010629","article-title":"High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.","volume":"94","author":"Guilhot","year":"2009","journal-title":"Haematologica"},{"key":"2019111808194456300_B54","first-page":"167","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"issue":"3","key":"2019111808194456300_B55","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of k-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"11","key":"2019111808194456300_B56","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models.","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"issue":"4","key":"2019111808194456300_B57","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians.","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2019111808194456300_B58","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/25\/5963\/1353379\/zh802512005963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/25\/5963\/1353379\/zh802512005963.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:39:29Z","timestamp":1574084369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/25\/5963\/30032\/Definitions-methodological-and-statistical-issues"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,21]]},"references-count":58,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2012,6,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-383711","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,21]]}}}